Examining the Incidence of Human Papillomavirus-Associated Head and Neck Cancers by Race and Ethnicity in the U.S., 1995–2005

BackgroundMany economic evaluations of human papillomavirus vaccination should ideally consider multiple disease outcomes, including anogenital warts, respiratory papillomatosis and non-cervical cancers (eg, anal, oropharyngeal, penile, vulvar and vaginal cancers). However, published economic evaluations largely relied on estimates from single studies or informal rapid literature reviews.MethodsWe conducted a systematic review of articles up to June 2016 to identify costs and utility estimates admissible for an economic evaluation from a single-payer healthcare provider’s perspective. Meta-analyses were performed for studies that used same utility elicitation tools for similar diseases. Costs were adjusted to 2016/2017 US$.ResultsSixty-one papers (35 costs; 24 utilities; 2 costs and utilities) were selected from 10 742 initial records. Cost per case ranges were US$124–US$883 (anogenital warts), US$6912–US$52 579 (head and neck cancers), US$12 936–US$51 571 (anal cancer), US$17 524–34 258 (vaginal cancer), US$14 686–US$28 502 (vulvar cancer) and US$9975–US$27 629 (penile cancer). The total cost for 14 adult patients with recurrent respiratory papillomatosis was US$137 601 (one paper).Utility per warts episode ranged from 0.651 to 1 (12 papers, various utility elicitation methods), with pooled mean EQ-5D and EQ-VAS of 0.86 (95% CI 0.85 to 0.87) and 0.74 (95% CI 0.74 to 0.75), respectively. Fifteen papers reported utilities in head and neck cancers with range 0.29 (95% CI 0.0 to 0.76) to 0.94 (95% CI 0.3 to 1.0). Mean utility reported ranged from 0.5 (95% CI 0.4 to 0.61) to 0.65 (95% CI 0.45 to 0.75) (anal cancer), 0.59 (95% CI 0.54 to 0.64) (vaginal cancer), 0.65 (95% CI 0.60 to 0.70) (vulvar cancer) and 0.79 (95% CI 0.74 to 0.84) (penile cancer).ConclusionsDifferences in values reported from each paper reflect variations in cancer site, disease stages, study population, treatment modality/setting and utility elicitation methods used. As patient management changes over time, corresponding effects on both costs and utility need to be considered to ensure health economic assumptions are up-to-date and closely reflect the case mix of patients.

Download Full-text

Human papillomavirus: a cause of some head and neck cancers?

The Medical Journal of Australia ◽

10.5694/j.1326-5377.2004.tb06362.x ◽

2004 ◽

Vol 181 (8) ◽

pp. 415-416 ◽

Cited By ~ 5

Author(s):

Barbara R Rose ◽

Christopher J O'Brien ◽

Wei Li

Keyword(s):

Human Papillomavirus ◽

Head And Neck ◽

Head And Neck Cancers

Download Full-text

Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey

Canadian Urological Association Journal ◽

10.5489/cuaj.5366 ◽

2018 ◽

Vol 13 (2) ◽

Author(s):

Michael E. Zavaski ◽

Julian Hanske ◽

Björn Löppenberg ◽

Alexander P. Cole ◽

Nawar Hanna ◽

...

Keyword(s):

Human Papillomavirus ◽

Race And Ethnicity ◽

Penile Cancer ◽

Preventive Measure ◽

Primary Care Providers ◽

Care Providers ◽

Cancer Knowledge ◽

Cross Sectional ◽

Health Insurance Status ◽

The U.S

Introduction: We aimed to assess the contemporary knowledge of human papillomavirus (HPV) and its association with penile cancer in a nationwide cohort from the U.S. Methods: We used the Health Information National Trends Survey (HINTS), a cross-sectional telephone survey performed in the U.S. initiated by the National Cancer Institute. The most recent iteration, HINTS 4 Cycle 4, was conducted in mail format between August 19 and November 17, 2014. Primary endpoints included knowledge of HPV and its causal relationship to penile cancer. Baseline characteristics included sex, age, education, race and ethnicity, income, residency, personal or family history of cancer, health insurance status, and internet use. Multivariable logistic regression assessed predictors of HPV and penile cancer knowledge. Results: An unweighted sample of 3376 respondents was extracted from the HINTS 4, Cycle 4. Whereas 64.4% of respondents had heard of HPV, only 29.5% of these were aware that it could cause penile cancer. Men were significantly less likely to have heard of HPV than women (odds ratio [OR] 0.32; 95% confidence interval [CI] 0.24–0.43). Older age; African-American, Asian, and “other race”; being married; from a lower education bracket; having a personal cancer history; and those without internet access were significantly less likely to have heard of HPV. None of our examined variables were independent predictors for the knowledge of the association of penile cancer and HPV. Conclusions: Our analysis of a large, nationally representative survey demonstrates that the majority of the American public is familiar with HPV, but lack a meaningful understanding between this virus and penile cancer. Primary care providers and specialists should be encouraged to intensify counselling about this significant association as a primary preventive measure of this potentially fatal disease.

Download Full-text

Human papillomavirus and head and neck cancers: emerging trends and improving survival

Australian and New Zealand Journal of Public Health ◽

10.1111/j.1753-6405.2012.00860.x ◽

2012 ◽

Vol 36 (2) ◽

pp. 195-196 ◽

Cited By ~ 2

Author(s):

Julia M.L. Brotherton ◽

Alicia N. Stein ◽

E. Lynne Conway ◽

David G. Regan ◽

Andrew Grulich ◽

...

Keyword(s):

Human Papillomavirus ◽

Head And Neck ◽

Head And Neck Cancers ◽

Emerging Trends

Download Full-text

Abstract 4896: Identification of the mechanisms of radiosensitization by human papillomavirus (HPV) in head and neck cancers cell lines

10.1158/1538-7445.am2014-4896 ◽

2014 ◽

Author(s):

Vanesa Bol ◽

Vincent Grégoire

Keyword(s):

Human Papillomavirus ◽

Head And Neck ◽

Cell Lines ◽

Head And Neck Cancers

Download Full-text

Human papillomavirus as a driver of head and neck cancers

British Journal of Cancer ◽

10.1038/s41416-019-0602-7 ◽

2019 ◽

Vol 122 (3) ◽

pp. 306-314 ◽

Cited By ~ 8

Author(s):

Maria Elisa Sabatini ◽

Susanna Chiocca

Keyword(s):

Human Papillomavirus ◽

Head And Neck ◽

Hpv Infection ◽

Head And Neck Cancers ◽

Molecular Characteristics ◽

Pathogenic Role ◽

Diagnostic Biomarkers ◽

Different Types ◽

High Risk Hpv ◽

Racial Ethnic

Abstract The human papillomavirus (HPV) family includes more than 170 different types of virus that infect stratified epithelium. High-risk HPV is well established as the primary cause of cervical cancer, but in recent years, a clear role for this virus in other malignancies is also emerging. Indeed, HPV plays a pathogenic role in a subset of head and neck cancers—mostly cancers of the oropharynx—with distinct epidemiological, clinical and molecular characteristics compared with head and neck cancers not caused by HPV. This review summarises our current understanding of HPV in these cancers, specifically detailing HPV infection in head and neck cancers within different racial/ethnic subpopulations, and the differences in various aspects of these diseases between women and men. Finally, we provide an outlook for this disease, in terms of clinical management, and consider the issues of ‘diagnostic biomarkers’ and targeted therapies.

Download Full-text

Survival-Associated Metabolic Genes in Human Papillomavirus-Positive Head and Neck Cancers

Cancers ◽

10.3390/cancers12010253 ◽

2020 ◽

Vol 12 (1) ◽

pp. 253 ◽

Cited By ~ 6

Author(s):

Martin A. Prusinkiewicz ◽

Steven F. Gameiro ◽

Farhad Ghasemi ◽

Mackenzie J. Dodge ◽

Peter Y. F. Zeng ◽

...

Keyword(s):

Human Papillomavirus ◽

Head And Neck ◽

Patient Survival ◽

Tricarboxylic Acid Cycle ◽

Predictive Biomarkers ◽

Head And Neck Cancers ◽

The Cancer Genome Atlas ◽

Metabolic Genes ◽

Hpv Status ◽

The Impact

Human papillomavirus (HPV) causes an increasing number of head and neck squamous cell carcinomas (HNSCCs). Altered metabolism contributes to patient prognosis, but the impact of HPV status on HNSCC metabolism remains relatively uncharacterized. We hypothesize that metabolism-related gene expression differences unique to HPV-positive HNSCC influences patient survival. The Cancer Genome Atlas RNA-seq data from primary HNSCC patient samples were categorized as 73 HPV-positive, 442 HPV-negative, and 43 normal-adjacent control tissues. We analyzed 229 metabolic genes and identified numerous differentially expressed genes between HPV-positive and negative HNSCC patients. HPV-positive carcinomas exhibited lower expression levels of genes involved in glycolysis and higher levels of genes involved in the tricarboxylic acid cycle, oxidative phosphorylation, and β-oxidation than the HPV-negative carcinomas. Importantly, reduced expression of the metabolism-related genes SDHC, COX7A1, COX16, COX17, ELOVL6, GOT2, and SLC16A2 were correlated with improved patient survival only in the HPV-positive group. This work suggests that specific transcriptional alterations in metabolic genes may serve as predictive biomarkers of patient outcome and identifies potential targets for novel therapeutic intervention in HPV-positive head and neck cancers.

Download Full-text